{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"14","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"dispersionType":"Inter-Quartile Range","groups":[{"description":"AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)","id":"OG000","title":"AZD6244"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients. Two patients still on study and have received 68 and 79 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Every cycle","title":"Number of Courses Received","type":"SECONDARY","unitOfMeasure":"courses"}